POM-V Prescription Required

Bovalto Respi 3 Suspension for Injection for Cattle

Active ingredients: Bovine parainfluenza virus 3, Bovine respiratory syncytial virus, Mannheimia haemolytica

Form

Injection

Species

Cattle

Manufacturer

Boehringer Ingelheim Animal Health UK Ltd

VMD MA No.

08327/5010

What it's used for

For active immunisation of cattle in the absence of maternally derived antibodies against: - parainfluenza 3 virus, to reduce virus excretion due to infect...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Bovine parainfluenza virus 3...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Bovalto Respi 3 Suspension for Injection for Cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

For active immunisation of cattle in the absence of maternally derived antibodies
against:
- parainfluenza 3 virus, to reduce virus excretion due to infection,
- bovine respiratory syncytial virus, to reduce virus excretion due to infection,
- Mannheimia haemolytica serotype A1, to reduce clinical signs and lung lesions.
Onset of immunity: 3 weeks.
Duration of immunity: 6 months.

Revised: August 2023
AN: 03119/2022Page 2 of 5

None.

Cattle:
Very common
(>1 animal / 10 animals
treated):
Injection site swelling*Common
(1 to 10 animals / 100 animals
treated):
Hyperthermia**Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Anaphylactic-type reactions***
Injection site pain****
* This swelling could reach up to 10 cm or more in diameter and may be associated
with pain, and usually progressively reduces and disappears within 6 weeks
after vaccination.
** Transient and slight, higher after the second injection (1.5 °C at most) lasting up to
3 days after vaccination.
*** Appropriate symptomatic treatment should be administered.
**** Associated with injection site swelling.

Revised: August 2023
AN: 03119/2022Page 3 of 5
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

Vaccinate healthy animals only.

Special precautions for use in animals:
Safety and efficacy studies were performed in sero-negative calves. The efficacy of
the vaccination has not been demonstrated in presence of antibodies. The level of
antibody response may be reduced by the presence of maternal antibodies. In the
presence of maternal antibodies, timing of initial vaccination of calves should be
planned accordingly.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.

No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case-by-
case basis.

Store and transport refrigerated (2 °C – 8 °C).
Do not freeze. Protect from light.

Zero days.

Revised: August 2023
AN: 03119/2022Page 4 of 5
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: Immunologicals for Bovidae; inactivated viral and
bacterial vaccines for cattle.
ATCvet code: QI02AL
The vaccine induces an active immunity against bovine respiratory syncytial virus,
parainfluenza 3 virus and Mannheimia haemolytica.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.